Sign In
Buy KYTX
$7.82
-0.0800 (-1.01%)
At Close: Jun 03, 2026
SAN DIEGO, Dec. 15, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) common stock pursuant and/or traceable
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX
08:07am, Sunday, 15'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securi
NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Ther
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) - February 7, 2025 Deadline to Join – Contact Levi & Korsinsky
07:20pm, Saturday, 14'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 14, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securi
The Schall Law Firm Encourages Stockholder Participation In A Securities Fraud Case Against Kyverna Therapeutics Inc
07:10pm, Saturday, 14'th Dec 2024
LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics,
NEW YORK, NY / ACCESSWIRE / December 14, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securi
NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Kyverna Th
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
08:35am, Saturday, 14'th Dec 2024
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Kyverna To Contact Him Directly To Discuss Their Options NEW YORK
NEW ORLEANS , Dec. 13, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 7, 2025 to file lead plaintiff applications in a securi
KYTX INVESTOR ALERT: Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
10:15pm, Friday, 13'th Dec 2024
SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) common stock pursuant and
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Kyverna Therapeutics, Inc. (“Kyverna” or th
LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics,
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securi
Kyverna Therapeutics, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the KYTX Class Action Lawsuit
04:18pm, Friday, 13'th Dec 2024
Robbins LLP is Investigating Allegations that Kyverna Therapeutics, Inc. (KYTK) Provided Investors with Misleading Information in Connection with its IPO
Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
04:05pm, Friday, 13'th Dec 2024
Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif. , Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutica
